Published in:
Open Access 01-08-2021 | Obesity | Correction
Correction to: The Effects of Acarbose on Non-Diabetic Overweight and Obese Patients: A Meta-Analysis
Published in: Advances in Therapy | Issue 8/2021
Login to get accessExcerpt
The original article is published with an error in Table 1. The correct Table 1 is given below.
Table 1
Characteristics and Jadad score of the included studies
|
Study (first author + year of publication)
|
Nation
|
Duration
|
Blinding
|
Randomistation
|
Diagnoses
|
Intervention for Acarbose/control
|
Mean daily acarbose dose
|
The Jadad score
|
|---|---|---|---|---|---|---|---|---|
|
Rachmani, R. 2004
|
Israel
|
24 weeks
|
Yes
|
Yes
|
Obesity, hypertension
|
Acarbose/placebo
|
50 mg tid
|
3
|
|
Bayraktar, F. 1998
|
Turkey
|
12 weeks
|
Yes
|
Yes
|
Obesity
|
Acarbose/placebo
|
150 mg qd 2 weeks/300 mg qd 10 weeks
|
3
|
|
Hauner, H. 2001
|
Germany
|
14 weeks
|
Yes
|
Yes
|
Obesity
|
Acarbose/placebo
|
50 mg–300 mg
|
3
|
|
Malaguarnera, M. 1999
|
Italy
|
20 weeks
|
Yes
|
Yes
|
Familial hypertriglyceridaemia
|
Acarbose/placebo
|
50 mg bid
|
4
|
|
Laube, H. 1998
|
Germany
|
12 weeks
|
Yes
|
Yes
|
Overweight with IGT
|
Acarbose/placebo
|
100 mg qd
|
3
|
|
Penna, I.A. 2007
|
Brazil
|
24 weeks
|
Yes
|
Yes
|
Obese, PCOS and insulin resistance
|
Acarbose/placebo
|
50 mg tid
|
6
|
|
Chiasson, J.L. 1996
|
Canada
|
16 weeks
|
Yes
|
Yes
|
Obese subjects with IGT
|
Acarbose/placebo
|
50 mg tid 2 weeks/100 mg tid 14 weeks
|
3
|